Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Oncology Consultations®: Exploring Novel Agents and Future Directions in HER2-Positive Metastatic Breast Cancer

Release Date: June 29, 2020
Expiration Date: June 29, 2021

Activity Overview

This Oncology Consultations® is a video-based program in which two experts use a case-based approach to discuss the treatment and management of HER2-positive metastatic breast cancer (MBC). In this activity the faculty focus on current management strategies for HER2-positive MBC, the integration of recent regulatory approvals into treatment algorithms, and the application of recent clinical trial results to individualize care for our patients in the clinic. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of HER2-positive MBC and to improve outcomes for their patients with this disease.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists, pathologists, and fellows interested in the treatment of breast cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with breast cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe clinical practice recommendations for HER2 testing as well as practical aspects related to HER2 testing in patients with breast cancer
  • Assess clinical trial data for current and emerging approaches for the treatment of patients with HER2-positive metastatic breast cancer
  • Discuss emerging strategies for the management of patients with low HER2 expression
  • Recognize the rationale supporting the role of targeting HER3 in patients with metastatic breast cancer, and how it relates to HER2-positive disease

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Sara A. Hurvitz, MD, FACP
Sara A. Hurvitz, MD, FACP
Associate Professor of Medicine,
Director Breast Cancer Research Program
Division of Hematology/Oncology UCLA
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Los Angeles, CA

Disclosures: Grant/Research Support: Ambrx, Amgen, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, GlaxoSmithKline, Eli Lilly, MacroGenics, Novartis, Immunomedics; Stock Shareholder: NKMax; Other: Travel – Eli Lilly.

Tiffany A. Traina, MD
Tiffany A. Traina, MD
Vice Chair, Oncology Care
Section Head, Triple Negative Breast Cancer Clinical Research Program
Clinical Director, Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Eisai Co, Pfizer, Novartis, Myriad Genetics, Innocrin Pharmaceuticals, AstraZeneca, Astellas Pharma; Consultant: Eisai Co, Medivation, Pfizer, AstraZeneca, Bayer, Immunomedics, Merck & Co, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By